141 related articles for article (PubMed ID: 30511495)
1. High p-mTOR expression is associated with recurrence and shorter disease-free survival in atypical meningiomas.
Barresi V; Lionti S; La Rocca L; Caliri S; Caffo M
Neuropathology; 2019 Feb; 39(1):22-29. PubMed ID: 30511495
[TBL] [Abstract][Full Text] [Related]
2. Osteopontin predicts the behaviour of atypical meningioma.
Lin CK; Tsai WC; Lin YC; Hueng DY
Histopathology; 2012 Jan; 60(2):320-5. PubMed ID: 22211290
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of EGFR expression in de novo and progressed atypical and anaplastic meningiomas: an immunohistochemical and fluorescence in situ hybridization pilot study.
Caltabiano R; Barbagallo GM; Castaing M; Cassenti A; Senetta R; Cassoni P; Albanese V; Lanzafame S
J Neurosurg Sci; 2013 Jun; 57(2):139-51. PubMed ID: 23486338
[TBL] [Abstract][Full Text] [Related]
4. Histopathological features to define atypical meningioma: What does really matter for prognosis?
Barresi V; Lionti S; Caliri S; Caffo M
Brain Tumor Pathol; 2018 Jul; 35(3):168-180. PubMed ID: 29671247
[TBL] [Abstract][Full Text] [Related]
5. Frequent AKT1E17K mutations in skull base meningiomas are associated with mTOR and ERK1/2 activation and reduced time to tumor recurrence.
Yesilöz Ü; Kirches E; Hartmann C; Scholz J; Kropf S; Sahm F; Nakamura M; Mawrin C
Neuro Oncol; 2017 Aug; 19(8):1088-1096. PubMed ID: 28482067
[TBL] [Abstract][Full Text] [Related]
6. Atypical and anaplastic meningiomas: prognostic implications of clinicopathological features.
Yang SY; Park CK; Park SH; Kim DG; Chung YS; Jung HW
J Neurol Neurosurg Psychiatry; 2008 May; 79(5):574-80. PubMed ID: 17766430
[TBL] [Abstract][Full Text] [Related]
7. AKT2 expression in histopathologic grading and recurrence of meningiomas.
Wang Q; Fan SY; Qian J; Wang JY; Lu YC; Hu GH; Luo C
Eur J Surg Oncol; 2014 Sep; 40(9):1056-61. PubMed ID: 24656454
[TBL] [Abstract][Full Text] [Related]
8. Apoptosis detected with monoclonal antibody to single-stranded DNA is a predictor of recurrence in intracranial meningiomas.
Konstantinidou A; Korkolopoulou P; Patsouris E; Mahera H; Hranioti S; Kotsiakis X; Davaris P
J Neurooncol; 2001 Oct; 55(1):1-9. PubMed ID: 11804277
[TBL] [Abstract][Full Text] [Related]
9. Benign versus atypical meningiomas: risk factors predicting recurrence.
Nowak A; Dziedzic T; Krych P; Czernicki T; Kunert P; Marchel A
Neurol Neurochir Pol; 2015; 49(1):1-10. PubMed ID: 25666766
[TBL] [Abstract][Full Text] [Related]
10. p-CREB expression in human meningiomas: correlation with angiogenesis and recurrence risk.
Barresi V; Branca G; Caffo M; Tuccari G
J Neurooncol; 2015 Mar; 122(1):87-95. PubMed ID: 25563814
[TBL] [Abstract][Full Text] [Related]
11. Association between laminin γ1 expression and meningioma grade, recurrence, and progression-free survival.
Ke HL; Ke RH; Li B; Wang XH; Wang YN; Wang XQ
Acta Neurochir (Wien); 2013 Jan; 155(1):165-71. PubMed ID: 23053286
[TBL] [Abstract][Full Text] [Related]
12. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
13. mTOR Signaling and Potential Therapeutic Targeting in Meningioma.
Pinker B; Barciszewska AM
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216092
[TBL] [Abstract][Full Text] [Related]
14. A Risk Score Based on 5 Clinico-Pathological Variables Predicts Recurrence of Atypical Meningiomas.
Fioravanzo A; Caffo M; Di Bonaventura R; Gardiman MP; Ghimenton C; Ius T; Maffeis V; Martini M; Nicolato A; Pallini R; Pegolo E; Pinna G; Sala F; Skrap M; Volpin V; Barresi V
J Neuropathol Exp Neurol; 2020 May; 79(5):500-507. PubMed ID: 32232472
[TBL] [Abstract][Full Text] [Related]
15. Expression of p40 (∆Np63) protein in meningiomas, an unexpected finding: immunohistochemical study and evaluation of its possible prognostic role.
Guadagno E; Del Basso De Caro M; Pignatiello S; Sciammarella C; Solari D; Cappabianca P; Maiuri F; Dones F
J Neurooncol; 2016 Sep; 129(3):405-413. PubMed ID: 27394131
[TBL] [Abstract][Full Text] [Related]
16. Recurrence of benign meningiomas: predictive value of proliferative index, BCL2, p53, hormonal receptors and HER2 expression.
Abdelzaher E; El-Gendi SM; Yehya A; Gowil AG
Br J Neurosurg; 2011 Dec; 25(6):707-13. PubMed ID: 20979437
[TBL] [Abstract][Full Text] [Related]
17. Mitotic count, brain invasion, and location are independent predictors of recurrence-free survival in primary atypical and malignant meningiomas: a study of 86 patients.
Vranic A; Popovic M; Cör A; Prestor B; Pizem J
Neurosurgery; 2010 Oct; 67(4):1124-32. PubMed ID: 20881577
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological variables, immunophenotype, chromosome 1p36 loss and tumour recurrence of 247 meningiomas grade I and II.
Ruiz J; Martínez A; Hernández S; Zimman H; Ferrer M; Fernández C; Sáez M; López-Asenjo JA; Sanz-Ortega J
Histol Histopathol; 2010 Mar; 25(3):341-9. PubMed ID: 20054806
[TBL] [Abstract][Full Text] [Related]
19. A study of UbcH10 expression and its association with recurrence of meningiomas.
Jiang L; Wang T; Bao Y; Qian J; Wu XJ; Hu GH; Lu YC
J Surg Oncol; 2012 Sep; 106(3):327-31. PubMed ID: 22095464
[TBL] [Abstract][Full Text] [Related]
20. MCM7 expression is a promising predictor of recurrence in patients surgically resected for meningiomas.
Winther TL; Torp SH
J Neurooncol; 2017 Feb; 131(3):575-583. PubMed ID: 27868157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
